Medpace Holdings, Inc. $MEDP Shares Sold by Mairs & Power Inc.

Mairs & Power Inc. decreased its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 8.7% in the third quarter, Holdings Channel.com reports. The institutional investor owned 69,583 shares of the company’s stock after selling 6,603 shares during the quarter. Mairs & Power Inc.’s holdings in Medpace were worth $35,777,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Clarkston Capital Partners LLC acquired a new stake in Medpace in the 2nd quarter valued at about $40,569,000. Cibc World Market Inc. acquired a new position in shares of Medpace during the 3rd quarter worth approximately $5,033,000. Brighton Jones LLC grew its position in shares of Medpace by 160.4% in the third quarter. Brighton Jones LLC now owns 4,060 shares of the company’s stock valued at $2,087,000 after purchasing an additional 2,501 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its position in shares of Medpace by 150.0% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 15,193 shares of the company’s stock valued at $8,080,000 after purchasing an additional 9,117 shares in the last quarter. Finally, Baillie Gifford & Co. increased its holdings in shares of Medpace by 12.0% in the third quarter. Baillie Gifford & Co. now owns 584,796 shares of the company’s stock valued at $300,679,000 after purchasing an additional 62,503 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Trading Up 0.7%

Shares of NASDAQ:MEDP opened at $453.64 on Tuesday. The company has a market capitalization of $12.87 billion, a price-to-earnings ratio of 29.65, a PEG ratio of 2.16 and a beta of 1.44. Medpace Holdings, Inc. has a 12-month low of $250.05 and a 12-month high of $628.92. The business has a 50-day moving average price of $520.96 and a 200 day moving average price of $539.27.

Medpace (NASDAQ:MEDP) last announced its earnings results on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, topping the consensus estimate of $4.18 by $0.49. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The company had revenue of $708.45 million during the quarter, compared to analyst estimates of $689.53 million. During the same quarter last year, the firm posted $3.67 earnings per share. Medpace’s revenue was up 32.0% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, equities research analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have issued reports on MEDP. BMO Capital Markets reaffirmed a “market perform” rating on shares of Medpace in a research note on Wednesday, February 11th. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 target price on the stock in a research note on Friday, February 13th. Wall Street Zen upgraded shares of Medpace from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. TD Cowen raised shares of Medpace from a “sell” rating to a “hold” rating and dropped their price target for the company from $462.00 to $419.00 in a research note on Wednesday, February 18th. Finally, Royal Bank Of Canada initiated coverage on shares of Medpace in a report on Tuesday, March 3rd. They set an “outperform” rating and a $522.00 price target for the company. Five equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $486.67.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.